2,5-Dimethoxy-4-iodoamphetamine (DOI) – DOI is a psychedelic amphetamine that was first synthesized by Alexander Shulgin, who described it in PiHKAL (1991). It has been used recreationally and is a common scientific research tool.
Like other members of the DOx class (e.g. DOM), DOI has a long duration of action. It’s not uncommon for people to be incapable of sleeping for 24 hours or more, particularly with strong+ doses.
As we still don’t fully understand its effects in humans, minimizing your use and taking common doses is wise.
Light: 0.75 – 1 mg
Common: 1 – 3 mg
Strong: 3 – 4 mg
Total: 16 – 30 hours (24+ hours is more common with strong+ doses)
Onset: 01:00 – 01:30
Research suggests that administration of (R)-DOI blocks pulmonary inflammation, mucus hyper-production, airway hyper-responsiveness and turns off key genes in in-lung immune response. These effects block the development of allergic asthma in a mouse model.
DOI is a 5-HT2A, 5-HT2B and 5-HT2C receptor agonist.
DOI has been shown to be an extremely potent inhibitor of tumour necrosis factor-alpha inflammation at picomolar concentrations in cell studies. TNF-alpha is an important target for research into degenerative conditions such as rheumatoid arthritis and Alzheimer’s disease, where the disease process involves tissue damage through chronic inflammation. This could make DOI and other 5-HT2A agonists an entirely new area for development of novel treatments for these conditions.
DOI has also been shown to induce rapid growth and reorganization of dendritic spines and synaptic connections with other neurons, processes known to underlie neuroplasticity.